Logo
x

Search

Subscribe Now

Eisai

Eisai and Biogen Reports the CHMP’s Positive Opinion of Lecanemab to Treat Early Alzheimer’s Disease

Eisai and Biogen Reports the CHMP’s Positive Opinion of Lecanemab to Treat Early Alzheimer’s Disease

  • November 15, 2024
Eisai’s Fycompa (perampanel) Injection Formulation Receives MHLW’s Marketing Authorization for Epilepsy

Eisai’s Fycompa (perampanel) Injection Formulation Receives MHLW’s Marketing Authorization for Epilepsy

  • January 18, 2024
Eisai and Biogen’s Leqembi (Lecanemab) Receives the NMPA’s Approval for the Treatment of Alzheimer’s Disease

Eisai and Biogen’s Leqembi (Lecanemab) Receives the NMPA’s Approval for the Treatment of Alzheimer’s Disease

  • January 9, 2024
Eisai to Launch Leqembi (Lecanemab) in Japan for the Treatment of Alzheimer’s Disease (AD)

Eisai to Launch Leqembi (Lecanemab) in Japan for the Treatment of Alzheimer’s Disease (AD)

  • December 13, 2023
Eisai and BioArctic Presented Results of Leqembi as Subcutaneous Dosage Form in P-III Trial for Alzheimer’s Disease CTAD 2023

Eisai and BioArctic Presented Results of Leqembi as Subcutaneous Dosage Form in P-III Trial for Alzheimer’s Disease CTAD 2023

  • October 26, 2023
Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study

Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study

  • July 5, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.